Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Disease Progression Clear all
Recruiting Phase 1Phase 2 Interventional

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

NCT04503265
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency, Prostate Cancer, Pancreatic Cancer
Interventions
AMXI-5001:Dose Escalation Phase I, AMXI-5001:Dose Expansion Phase II
Drug
Lead sponsor
AtlasMedx, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Sep 23, 2026, 8:23 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Postoperative Oral Methadone After Major Spine Surgery; Safety, Feasibility and Efficacy in Prevention of Progression to Chronic Opioid Usage at 3 Months

NCT05693675
View directory record Official record
Conditions
Spine Surgery
Interventions
Postoperative methadone, Postoperative placebo, Rescue Analgesia
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 23, 2026, 8:23 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide

NCT02270567
View directory record Official record
Conditions
Neuroendocrine Tumor, Carcinoid, Neuroendocrine Carcinoma
Interventions
NETest
Device
Lead sponsor
Wren Laboratories LLC
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2030
U.S. locations
1
States / cities
Branford, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Sep 23, 2026, 8:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Kubota Glass Parameter Refinement Study

NCT06085430
View directory record Official record
Conditions
Myopia, Myopia, Progressive, Vision Disorders
Interventions
Kubota Glass
Device
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
8 Years to 24 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Sep 23, 2026, 8:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Lymphedema Progression Screening Using MRI

NCT02611557
View directory record Official record
Conditions
Lymphedema, Breast Cancer
Interventions
Manual lymphatic drainage therapy
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 25, 2019 · Synced Sep 23, 2026, 8:23 PM EDT
Not yet recruiting Not applicable Interventional

Contact Lenses to Slow Myopia Progression in Adults

NCT07747311
View directory record Official record
Conditions
Myopia, Myopia Progression
Interventions
Dual Focus Soft Contact Lens, Single Vision Soft Contact Lens
Device
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 30 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 23, 2026, 8:23 PM EDT
Terminated Not applicable Interventional

A Study Looking at the Use of Biomarkers to Provide Early Indication of Acute Kidney Injury in Patients With Sepsis (Limiting AKI Progression In Sepsis)

NCT04434209
View directory record Official record
Conditions
Sepsis, Acute Kidney Injury, Septic Shock
Interventions
Subject management guided by NephroCheck® test, Standard of Care
Device · Other
Lead sponsor
BioMérieux
Industry
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Shreveport, Louisiana • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 23, 2026, 8:23 PM EDT
Not yet recruiting No phase listed Observational

Symptom Trajectory Approaches to Research

NCT07804875
View directory record Official record
Conditions
Advanced Cancer, Metastatic Disease, Cancer Treatment, Progressive Disease, Recurrent Cancer
Interventions
Health surveys
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
8 Years to 18 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Los Angeles, California • New York, New York • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 23, 2026, 8:23 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

NCT02271139
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Alectinib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
45
States / cities
Bimingham, Alabama • Daphne, Alabama • Mobile, Alabama + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Sep 23, 2026, 8:23 PM EDT
Completed Not applicable Interventional Results available

Clinical Utility of a PCR Compared to Culture and Sensitivity Testing for the Management of cUTI in Adults.

NCT06996301
View directory record Official record
Conditions
Urinary Tract Infection Complicated, Urinary Tract Infection (cUTI), Urinary Tract Infection (Diagnosis)
Interventions
Treatment guided by the PCR results, Treatment guided by the C&S results
Diagnostic Test
Lead sponsor
Doc Lab Inc
Industry
Eligibility
18 Years and older
Enrollment
773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
San Jose, California • Albany, Georgia • Evans, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 23, 2026, 8:23 PM EDT
Completed Phase 2 Interventional

Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease

NCT01850381
View directory record Official record
Conditions
Parkinson's Disease
Interventions
GM608, Placebo Comparator
Drug
Lead sponsor
Genervon Biopharmaceuticals, LLC
Industry
Eligibility
30 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Sep 23, 2026, 8:23 PM EDT
Not listed Phase 4 Interventional

Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)

NCT01486771
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Macugen ® (pegaptanib sodium)
Drug
Lead sponsor
Valley Retina Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2011 · Synced Sep 23, 2026, 8:23 PM EDT
Recruiting Phase 2 Interventional

A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer

NCT05751434
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Localized Prostate Carcinoma
Interventions
Exercise Therapy
Behavioral
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
10
States / cities
Durate, California • Los Angeles, California • Hartford, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 23, 2026, 8:23 PM EDT
Terminated No phase listed Observational

Study of Diroximel Fumarate in the Real-World Setting

NCT04746976
View directory record Official record
Conditions
Relapsing Forms of MS
Interventions
Diroximel Fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
18
States / cities
West Hollywood, California • Washington D.C., District of Columbia • Louisville, Kentucky + 15 more
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Sep 23, 2026, 8:23 PM EDT
Completed Phase 2 Interventional

Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel

NCT00082134
View directory record Official record
Conditions
Hormone-refractory Prostate Cancer
Interventions
ILX651
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
19 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
12
States / cities
Tucson, Arizona • Lenexa, Kansas • Overland Park, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Sep 23, 2026, 8:23 PM EDT
Completed No phase listed Observational

The Natural History of Asymptomatic Rotator Cuff Tears

NCT00923858
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Sep 23, 2026, 8:23 PM EDT
Completed Not applicable Interventional

Exercise and RP (AVAMC and Emory)

NCT03381235
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Spin exercise
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Sep 23, 2026, 8:23 PM EDT
Terminated Phase 2 Interventional Results available

Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists

NCT00447226
View directory record Official record
Conditions
Cancer
Interventions
Oral lapatinib tablets or placebo tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
20
States / cities
Denver, Colorado • Indianapolis, Indiana • Overland Park, Kansas + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Sep 23, 2026, 8:23 PM EDT
Completed Phase 2Phase 3 Interventional

A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.

NCT03231878
View directory record Official record
Conditions
Adrenoleukodystrophy
Interventions
MIN-102, Placebos
Drug
Lead sponsor
Minoryx Therapeutics, S.L.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
3
States / cities
Stanford, California • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Sep 23, 2026, 8:23 PM EDT
Terminated Phase 4 Interventional Results available

A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?

NCT02287025
View directory record Official record
Conditions
Physician Education
Interventions
Regorafenib (Stivarga, BAY73-4506), iPAD application, Bayer specialist
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
17
States / cities
Anniston, Alabama • Anaheim, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Sep 23, 2026, 8:23 PM EDT
Not yet recruiting Phase 2 Interventional

Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

NCT07703436
View directory record Official record
Conditions
Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma, Glioma, IDH1-mutant Glioma, Oligodendroglioma, Oligodendroglioma IDH-1 Mutant and 1/p19q-codeleted, Astrocytoma IDH Mutant Grade 3, Astrocytoma IDH Mutant Grade 2
Interventions
Safusidenib
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 23, 2026, 8:23 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

NCT07049055
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
E-EDV-D682, EDV-GC, Gemcitabine, Nab paclitaxel.
Drug
Lead sponsor
Engeneic Pty Limited
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
El Segundo, California • Summit, New Jersey • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 23, 2026, 8:23 PM EDT
Not yet recruiting Phase 2 Interventional

Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy

NCT07578025
View directory record Official record
Conditions
Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03, Computed Tomography, Zanzalintinib
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 23, 2026, 8:23 PM EDT
Completed Phase 3 Interventional

Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.

NCT00225264
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone, Glimepiride
Drug
Lead sponsor
Takeda
Industry
Eligibility
45 Years to 85 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Sep 23, 2026, 8:23 PM EDT